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Abstract
Background
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder in which infection
with Chlamydia pneumoniae (Cpn) has been associated. Cpn is an obligate intracellular
respiratory pathogen that may enter the central nervous system (CNS) following infection and
trafficking of monocytes through the blood-brain barrier. Following this entry, these cells
may secrete pro-inflammatory cytokines and chemokines that have been identified in the AD
brain, which have been thought to contribute to AD neurodegeneration. The objectives of this
work were: (i) to determine if Cpn infection influences monocyte gene transcript expression
at 48 hours post-infection and (ii) to analyze whether pro-inflammatory cytokines are
produced and secreted from these cells over 24 to 120 hours post-infection.

Methods
Gene transcription was analyzed by RT-PCR using an innate and adaptive immunity
microarray with 84 genes organized into 5 functional categories: inflammatory response, host
defense against bacteria, antibacterial humoral response, septic shock, and cytokines,
chemokines and their receptors. Statistical analysis of the results was performed using the
Student's t-test. P-values ≤ 0.05 were considered to be significant. ELISA was performed on
supernatants from uninfected and Cpn-infected THP1 monocytes followed by statistical
analysis with ANOVA.

Results
When Cpn-infected THP1 human monocytes were compared to control uninfected monocytes
at 48 hours post-infection, 17 genes were found to have a significant 4-fold or greater
expression, and no gene expression was found to be down-regulated. Furthermore, cytokine
secretion (IL-1β, IL-6, IL-8) appears to be maintained for an extended period of infection.

Conclusions
Utilizing RT-PCR and ELISA techniques, our data demonstrate that Cpn infection of THP1
human monocytes promotes an innate immune response and suggests a potential role in the
initiation of inflammation in sporadic/late-onset Alzheimer’s disease.

Keywords
Chlamydia pneumoniae, Inflammation, Innate immunity, Alzheimer’s disease, Gene
expression

Background
Studies from our laboratory have implicated infection with Chlamydia pneumoniae (Cpn) in
the pathogenesis of sporadic late-onset Alzheimer’s disease (LOAD) [1-3]. We have
previously identified infection within monocytes, macrophages, microglia, astroglia, and
neurons in the Alzheimer's disease (AD) brain. One mechanism by which the organism may
gain access into the brain is following peripheral infection of monocytes [4,5]. We are
investigating Cpn infection of monocytes in vitro to determine how infection may promote
changes in inflammatory gene and protein expression because monocytes have been
demonstrated to be altered with regards to expression of cytokines, Aβ amyloid clearance,
and apoptosis in Alzheimer's disease patients [6-9].
Although the specific etiology of LOAD has remained elusive, what has emerged is strong
evidence that inflammation is a focal point in the neuropathogenesis process [10-13].
Associations between AD and many inflammatory biomarkers, including IL-1β, IL-2, IL-4,
IL-6, IL-8, IL-10, IL-12, IL-18, IFN-γ, TNF-α, tumor growth factor beta (TGF-β), and Creactive protein (CRP) have all been well documented [14] (for reviews see [12,14]).
Activated microglia and astroglia have been identified near and around neuritic senile plaques
in the AD brain along with pro-inflammatory cytokines IL-1β, IL-6, and TNF-α
[11,13,15,16], suggesting that a pro-inflammatory state could be responsible for neurotoxicity
associated with AD [17].
As the primary immune cells within the human brain, microglia act as the functional
equivalent of macrophages inside the central nervous system (CNS) [18]. Microglia are
activated in response to an infection or injury within the brain and are speculated to be
responsible for neurotoxicity in diseases such as multiple sclerosis and Parkinson’s disease
[18,19]. Experiments in rats have shown that microglia phagocytize and internalize amyloid,
apparently in an effort to clear amyloid from the CNS [20]. Related data also indicate that
following phagocytosis, Aβ amyloid may remain stored and un-degraded within the activated
microglia [21].

Microglial activation as a consequence of internalization of Aβ may activate neighboring
microglia and astrocytes through a 'bystander effect'. These activated glia, in turn, may
promote further Aβ 1-40 and 1-42 production [22]. This cycle appears to perpetuate
inflammation, as well as Aβ production and deposition [10,23]. Activated microglia release a
pool of pro-inflammatory factors including IL-1β, IL-6, TNF-α, nitric oxide, IL-8, and
macrophage inflammatory protein-1 [24,25]. As IL-1β and IL-6 are major pro-inflammatory
cytokines involved with neuronal dysfunction, glia producing these cytokines may start a
self-activating cascade referred to as a lethal 'cytokine cycle' [10,11,25]. According to the
cytokine cycle, IL-1 is released from activated glia across AD brain regions independent of
the initial stimulus. This primary event drives the cascade of cytokine release which promotes
the neuropathological changes associated with AD.
A correlation between activated astroglia and amyloid plaques appears to exist, as astroglia,
which greatly outnumber microglia in the brain, often aggregate at the site of Aβ deposits
[26,27]. Substantial evidence indicates that astroglia are directly involved in the degradation
and clearance of Aβ [26], and when activated, they also promote inflammation by secreting
IL-1β and IL-6 [28]. These pro-inflammatory mediators also have been shown to activate
astroglia resulting in an increased production of Aβ 1-40/1-42 peptides, thus demonstrating a
positive feedback loop for the generation of amyloid [23,29]. Chronic glial activation may
perpetuate a chain reaction where successive axonal target regions fall victim to additional
neuronal damage, thereby continuing the cycle [11].
Furthermore, astroglia have been shown to generate other pro-inflammatory mediators such
as monocyte chemoattractant peptide-1 (MCP1/CCL2), RANTES, and TNF-α in reaction to
the presence of Aβ [30]. CCL2 is a potent chemoattractant molecule for monocytes, and thus,
monocytes may be both initiators and perpetuators of the cycle, suggesting that monocytes
could be significant contributors to the pro-inflammatory cascade.
The current study addresses infection of human THP1 monocytes in vitro with the laboratory
strain of Cpn, AR39, to determine how infection can affect the regulation of gene transcripts
for innate and adaptive immunity. In this regard, infection may be a stimulus for proinflammatory cytokine expression which may start the cascade that results in initial amyloid
processing and deposition observed in Alzheimer's disease [1,31,32]. Analysis of this
cytokine expression will demonstrate how infection of monocytes could set the stage for
initiating inflammation in this disease.

Materials and methods
THP1 human monocytes
THP1 human monocytes obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA), were propagated at a concentration of 1 x 106 cells/ml RPMI 1640
(ATCC) + 10% FBS (Cellgro Thermo Fisher Scientific, Pittsburgh, PA, USA) growth media
(GM) in a 37?C incubator with 5% CO 2.

Infection with Chlamydia pneumoniae (Cpn)
A human respiratory isolate of Cpn, laboratory strain AR39 obtained from the ATCC, was
used to infect THP1 monocytes in vitro. Prior to inoculation of monocytes, each vial of Cpn
was thawed and sonicated for 2 minutes. THP1 cells were spun down, washed with Hank’s
Balanced Salt Solution (HBSS), and resuspended in 1 ml of GM at a concentration of 1 x 106
cells/ml. To this volume, 400 μl of Cpn at a multiplicity of infection (MOI) of 1 (1 x 106
infectious units IFU) were added. The cells were allowed to incubate for 1 hour at 37?C with
5% CO2 in a T-25 flask, after which 3.6 ml of GM was added for a final volume of 5 ml.
Cells were then incubated for the allotted times (24 to 120 hours). For 96- and 120-hour
infections, another 5 ml of GM was added at the 48-hour time point.
To validate and determine percent of infection of our monocytes at each time point, 2 x 105
cells at 1 x 105 cells per slide were cytospun and analyzed by immunocytochemistry. In brief,
cytospun cells were fixed using Cytofix/Cytoperm (BD Cytofix/Cytoperm 554722; BD
Biosciences, San Jose, CA, USA) for 30 minutes, washed 2 x 5 minutes with HBSS, labeled
with a fluorescein isothiocynanate (FITC)-directly conjugated anti-chlamydial antibody,
Fitzgerald 61C75 (Fitzgerald Industries International, Acton, MA, USA) for 1 hour at 37?C,
and counterstained using bisbenzimide (Sigma bisbenzimide B2883, Sigma-Aldrich, St
Louis, MO, USA) and coverslipped. The slides were imaged on a Nikon E80i microscope
using the NIS-Elements AR 3.0 software (Nikon Inc., Melville, NY, USA). Five random
fields per slide per time point for each experiment at 40X magnification were analyzed and
counted (total infected cells/total cells x 100 = percent infected). Average percent infection
for 24 to 120 hours was 81, 85, 92, 92, and 90, respectively.
Infection time for the real time-polymerase chain reaction (RT-PCR) experiments was 48
hours and the infection times for the ELISA cytokine analyses were 24 to 120 hours.
Although gene changes were analyzed only at 48 hours post-infection, the time at which an
acute infection is established, we wanted to obtain specific data for cytokine changes over
longer time points as the inflammation in AD appears to become more chronic in nature
following its initiation. In a comparable manner, parallel control uninfected flasks at the same
cellular concentration received only media for the specified incubation times.
At the specified times for analysis, both uninfected and infected cells were removed from the
incubator and transferred to individual 15-ml tubes. To ensure complete cell recovery,
another 5 ml of fresh GM was added to the 24-, 48- and 72-hour flasks, followed by cell
scraping to release any remaining cells prior to transfer to the 15-ml tubes. The final volume
for all time points was 10 ml. The cells were pelleted at 1,000 x g for 5 minutes. The
supernatants were collected for ELISA analysis into new 15-ml tubes and frozen at −80°C.
The pellet was resuspended in 5 ml of HBSS and counted. Cells were again pelleted and
either kept on ice or snap frozen in liquid nitrogen prior to preparation for RT-PCR.

RNA isolation
Using the RNeasy Mini kit (Qiagen Inc., Valencia, CA, USA), RNA was extracted from cell
pellets according to manufacturer’s directions. In brief, cells were mixed with RLT buffer,
pipetted onto a QIAshredder™ spin column and centrifuged for 2 minutes at 15,000 x g to
lyse and homogenize the cells. Ethanol was mixed with this sample, transferred to an RNeasy
spin column, centrifuged for 15 seconds at 8,000 x g and the flow-through discarded. RW1
Buffer (700 μl) was added, centrifuged for 15 seconds at 8,000 x g and flow-through
discarded. RPE Buffer (500 μl) was added to the RNeasy spin column, centrifuged for 15
seconds at 8,000 x g, flow-through discarded, another 500 μl of RPE Buffer was added and
centrifuged for 2 minutes at 8,000 x g. Finally, the RNA was eluted from the spin column in
RNase-free water (30 μl).

First strand synthesis
Using the RT2 First Strand Kit (SABiosciences, Qiagen, Valencia, CA, USA), cDNA was
produced from 1 μg of RNA following the First Strand Kit protocol according to
manufacturer’s directions. To eliminate any contaminating genomic DNA carryover, a
Genomic DNA Elimination step preceded the reverse transcription reaction. Following
reverse transcription, 91 μl of RNase, DNase-free water was added to each 20 μl of cDNA.
This cDNA was either used immediately for RT-PCR or frozen at −20°C until use.

Real time-polymerase chain reaction (RT-PCR)
RT-PCR was used to determine the level of gene transcription using the Human Innate and
Adaptive Immune Responses RT2 Profiler™ PCR Array (PAHS-052) from SABiosciences
(Qiagen, Valencia, CA, USA). The cDNA samples were spun briefly to remove any
particulate material. The master mix cocktail was prepared according to the specifications for
the 96-well plate.
Twenty-five microliters of the experimental cocktail was added to each well of the 96-well
RT-PCR array plate. The plate was run on the Applied Biosciences 7000 Sequence Detection
System (Life Technologies Corporation, Carlsbad, CA, USA) utilizing ABI Prism 7000 SDS
Software and then analyzed using software on the SABiosciences website [33]. The data are
normalized to the control housekeeping genes RPL13A, GAPDH and ACTB. The website
calculates fold change (fold difference) by the 2-ΔΔCT method with the control being the
uninfected THP1 cells. Statistical analysis of the results was done using Student’s t-test. Pvalues below 0.05 were considered to be significant. RT-PCR experiments were performed
using cDNA from 4 separate experiments comparing 48 hour Cpn-infected THP1 monocytes
to parallel uninfected monocytes grown for 48 hours.

Multi-analyte ELISA array
Using the Multi-Analyte ELISArray Kit protocol version 1.4 from SABiosciences (Qiagen,
Valencia, CA, USA), a multi-array ELISA was performed using the supernatants collected
during the harvest of uninfected and Cpn-infected THP1 monocytes according to
manufacturer’s directions. In brief, the supernatants were thawed and centrifuged for 10
minutes at 1,000 x g to remove any particulate material. Fifty microliters of each
experimental sample, in triplicate, was added to the array that included specific cytokine

capture antibodies: IL-1α IL-1β, IL-2, IL-4, IL-6, IL-8, IL-12, IL-17α, IFN-γ, TNF-α and GM
CSF (colony stimulating factor) and allowed to incubate at room temperature (RT) for 2
hours.
After numerous buffer washes, 100 μl of the diluted biotinylated detection antibodies were
added to the appropriate wells of the ELISA plate and incubated in the dark for 1 hour at
room temperature (RT). Following this incubation, the plate was washed and 100 μl of dilute
Avidin-horseradish peroxidase (HRP) were added into all wells and incubated in the dark for
30 minutes at RT. After this incubation, development and stop solutions were added followed
by detection of absorbance changes at 450 and 570 nm on a UV/VIS spectrophotometer
(Nicolet Evolution 100, Thermo Fisher Scientific, Pittsburgh, PA, USA).
The raw data obtained from the absorbance readings were normalized to the cell counts of
each sample. Averages of all triplicates were determined along with standard deviations and
an analysis of variance (ANOVA) statistical test was performed. Time points of 24, 48 and
72 hours were tested in triplicate in 5 separate experiments, while the 96- and 120-hour time
points were tested in triplicate in 4 separate experiments.

Single-analyte ELISA array
Using the Single-Analyte ELISArray Kit protocol version 1.4 from SABiosciences (Qiagen,
Valencia, CA, USA), a single-analyte ELISA was performed for IL-1β, IL-6, and IL-8
according to manufacturer’s directions using the supernatants collected during the harvest. In
brief, the supernatants were thawed and centrifuged for 10 minutes at 1,000 x g to remove
any particulate material. Preparation of the antigen standard dilution was prepared by serial
dilution. As with the multi-analyte array, the array was prepared using 50 μl of each
experimental sample in triplicate and allowed to incubate at RT for 2 hours, followed by
incubation with the detection antibodies. Similar to the previous multi-analyte arrays, AvidinHRP was used to determine binding of the detection antibodies to the cytokines of interest.
After color development as described above, absorbance readings were taken at 450 and 570
nm and the raw data were normalized. Averages of all triplicates were found along with
standard deviations and an ANOVA statistical test was performed. As with the multi-analyte
array, times of 24, 48 and 72 hours were tested in 5 separate experiments and those of 96 and
120 hours were tested from 4 separate experiments.

Results
Real time-polymerase chain reaction
Gene transcription was analyzed by RT-PCR using an innate and adaptive immunity
microarray with 84 genes organized into 5 functional categories: inflammatory response,
septic shock, cytokines, chemokines and their receptors, host defense against bacteria, and
antibacterial humoral response. When Cpn-infected THP1 human monocytes were compared
to control uninfected monocytes at 48 hours post-infection, 17 gene transcripts (Table 1) had
significant increases (P-values ≤ 0.05).

Table 1 Innate and adaptive immunity gene transcripts increased at 48 hours in
Chlamydia pneumoniae (Cpn)-infected THP1 cells
Inflammatory response

Host defense against bacteria

Gene symbol
IL1F5
IL1F8
IL1RN
IRAK2
NLRC4
TLR8
TNF
DEFB4
DMBT1
NFKBIA

PTAFR
COLEC12
CYBB
Cytokines, chemokines, and their CCL2
receptors
IFNB1
IL6
Septic shock
SERPINA1
Antibacterial response

Gene name
Interleukin 1 family, member 5 (delta)
Interleukin 1 family, member 8 (eta)
Interleukin 1 receptor antagonist
Interleukin 1 receptor associated kinase 2
NLR family, CARD domain containing 4
Toll-like receptor 8
Tumor necrosis factor (TNF superfamily, member 2)
Defensin, beta 4
Deleted in malignant brain tumors 1
Nuclear factor of kappa light polypeptide gene enhancer in
B-cells inhibitor, alpha
Platelet-activating factor receptor
Collection sub-family member 12
Cytochrome B-245, beta polypeptide
Chemokine (C-C motif) ligand 2
Interferon, beta 1, fibroblast
Interleukin 6 (Interferon, beta 2)
Serpin peptidase inhibitor, clade A
(alpha-1 antiproteinase, antitrypsin), member 1

Transcripts analyzed included those associated with the host response to pathogens, including
inflammatory response genes, antibacterial humoral response genes, cytokines, chemokines
and their receptors, genes involved in bacterial host defense mechanisms and septic shock.
Seven gene transcripts from the inflammatory response category (see Table 1 and Figure 1)
had at least a four-fold increase in expression. Toll-like receptor (TLR)8 transcripts had the
most dramatic significant fold increase of 33.73, whereas lesser increases were observed for
TNF (4.26), NLRC4 (4.34), IL1F5 (8.79), IL1F8 (11.29), and the IL-1 receptor genes IL1RN
(10.83) and IRAK2 (6.66).
Figure 1 Inflammatory response, cytokines, chemokines and their receptors, and septic
shock gene transcripts. Transcript increases of THP1 human monocytes at 48 hours post
Cpn infection. Only significant gene transcripts with a 4-fold or greater increase compared to
uninfected THP1 cells are included (P-values ≤ 0.05).
Gene transcripts for 3 cytokines, chemokines and their receptors demonstrated significant >
4-fold increases (Figure 1). CCL2 transcripts had the most dramatic significant fold increase
of 1,136.10 within this category. Expression of IFNB1 and IL-6 both had significant increases
of 11.02 and 6.69, respectively. Under septic shock (Figure 1), only 1 gene (SERPINA1,
16.50) was found to have a significant increase in expression.
Transcript changes with regard to the host defense against bacteria revealed four gene
transcripts to be significantly up-regulated with > four-fold increases (Figure 2). PTAFR had
the most dramatic significant increase in expression with 22.47 fold change. Under
antibacterial humoral response (Figure 2), CYBB gene expression had the most significant
increase of 17.15, while COLEC12 had a significant increase of 5.64.

Figure 2 Host defense against bacteria and antibacterial humoral response gene
transcripts. Gene transcript increases of THP1 human monocytes at 48 hours post Cpn
infection. Only significant gene transcripts with a 4-fold or greater increase compared to
uninfected THP1 cells are included; data are plotted on a log scale, (P-values ≤ 0.05).
In summary, of all the 84 genes in the Innate and Adaptive Immunity pathway microarray,
expression of CCL2 showed the most dramatic significant increase. Other cytokine gene
transcripts of note such as IL-6 and TNF showed smaller, but significant fold increases in
expression.

ELISA
ELISA techniques were performed using the supernatants of uninfected and Cpn-infected
THP1 human monocytes. A multi-analyte ELISArray provided a general overview for
secretion per 1 x 106 cells of 12 cytokines. This ELISArray showed that the cytokines IL-1β,
IL-6, and IL-8 have increased secretion when the cells are Cpn-infected, thus single-analyte
ELISArrays were performed to further evaluate these 3 cytokines.

IL-1β
A single-analyte ELISArray for IL-1β (Figure 3) demonstrated a significant increase (P-value
≤ 0.05) in cytokine secretion in the Cpn-infected THP1 human monocytes compared to
uninfected THP1 cells for all the time points. In Cpn-infected THP-1 cells, a significant
decrease in levels of secreted IL-1β at the 96-hour and 120-hour time points relative to the
24-hour time point was observed. Decreased secretion of IL-1β also was significant for the
Cpn-infected THP1 cells at the 72-, 96- and 120-hour time points compared to the levels at
48 hours. At 120 hours, there was significantly lower secretion of IL-1β compared to 72
hours.
Figure 3 Average secretion of IL-1β. Average secretion of IL-1β by 106 cells at the 24-, 48and 72-hour time points repeated in 5 individual experiments, and the 96 hours and 120 hours
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05)
within time points (uninfected to infected), while the (#) symbol indicates significance (Pvalue ≤ 0.05) between time points (infected to infected).

IL-6
Analysis of the IL-6 single-analyte ELISArray plate revealed that more IL-6 is secreted from
Cpn-infected THP1 cells than uninfected THP1 cells at all times (Figure 4); this difference
was significant. Moreover, there was an overall significant decrease in IL-6 secretion from
Cpn-infected THP1 cells over the entire time course of infection.
Figure 4 Average secretion of IL-6. Average secretion of IL-6 by 106 cells at the 24-, 48and 72-hour time points repeated in 5 individual experiments and the 96 hours and 120 hours
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05)
within time points (uninfected to infected), while the (#) symbol indicates significance (Pvalue ≤ 0.05) between time points (infected to infected).

IL-8
Results of the IL-8 single-analyte ELISArray plate revealed an initial significant increase (Pvalue ≤ 0.05) in the 24-, 48-, 72-, 96- and 120-hour time points between Cpn-infected cells
compared to uninfected THP1 (Figure 5). Similar to what was observed with IL-1β, at 96 and
120 hours, there was a marked decrease in secretion of IL-8 from the Cpn-infected THP1
cells compared to the Cpn-infected cells at earlier time points. Furthermore, the decreases
seen at 96 and 120 hours as compared to 24 and 48 hours were significant (P-value ≤ 0.05),
as was the decrease seen from the 48-hour time to the 72-hour time point, and the decrease
seen from 72 hours to the 96- and 120-hour time points.
Figure 5 Average secretion of IL-8. Average secretion of IL-8 by 106 cells at the 24-, 48and 72-hour time points repeated in 5 individual experiments and the 96 hours and 120 hours
repeated in 4 individual experiments. The (*) symbol indicates significance (P-value ≤ 0.05)
within time points (uninfected to infected), while the (#) symbol indicates significance (Pvalue ≤ 0.05) between time points (infected to infected).

Discussion
Chlamydial species have been associated with a spectrum of diseases of clinical significance
shown to be a result of immunopathogenesis. Although the immune response is central for
disease manifestations, there is still much to learn about the mechanisms that initiate and
sustain the inflammatory response to Cpn infection [34,35]. Secretion of pro-inflammatory
cytokines occurs when host cells, including monocytes and microglia, are infected with Cpn
[35,36]. The current study evaluates changes in THP1 monocyte gene expression at 48 hours
post-infection (acute) and in specific cytokine production/secretion over a 5-day (chronic)
course of infection. Our data indicate that infection of monocytes with Cpn results in
significant changes in host gene transcription and secretion of pro-inflammatory cytokines.
Furthermore, cytokine secretion (IL-1β, IL-6, IL-8) appears to be maintained for an extended
period of infection, suggesting that a more chronic or persistent infection can maintain the
pro-inflammatory condition. Work by others has suggested that similar cytokines were
secreted after Cpn infection of THP1 monocytes, although shorter periods of infection with a
higher multiplicity of infection (ie, MOI = 5) were evaluated [37]. Thus, our data suggest that
Cpn-infected monocytes at a modest level of infection (ie, MOI = 1) can promote an acute
and sustained pro-inflammatory state.
Previous work has shown that Cpn can infect multiple cell types including endothelial cells,
epithelial cells, smooth muscle cells, and peripheral blood mononuclear cells [1,38,39]. Cpninfected macrophages have been found in sites such as the peritoneum and spleen following
respiratory inoculation of New Zealand white rabbits [40]. These findings suggest that the
migratory capabilities of peripheral blood monocytes may help to facilitate systemic infection
[41]. Moreover, infection of human monocytes with Cpn appears to enhance their migration
across an in vitro model of the blood-brain barrier (BBB) comprised of a human brain
microvascular endothelial cell layer [4]. Previous studies have shown that infection in the
lung is the main stimulus for monocytic and lymphocytic infiltration leading to potential
dissemination of infection into the circulation [40,42]. Blood vessels and monocytes in AD
brain tissue have been shown to be infected with Cpn, thus we postulate that Cpn entering the
circulation upon infection of monocytes could result in access to the CNS through the BBB
[4,5,43]. With regards to LOAD, Cpn has been studied as a possible etiologic agent [1,2] and

supporting evidence for Cpn in the etiopathogenesis of AD was provided by a study by Little
et al. 2004 which revealed amyloid deposits resembling plaques found in AD brains in the
brains of non-transgenic BALB/c mice following intranasal infection with Cpn [42].
As discussed previously, numerous cytokines have been shown to be involved in
neuroinflammation in AD, and previous work by others has implicated high levels of IL-1
directly in neuronal degeneration [44,45]. IL-1β is a member of the interleukin 1 cytokine
family and is produced by endothelial cells, some epithelial cells, and also by activated
macrophages as a pro-protein, which is proteolytically processed to its active form by IL-1β
convertase. This cytokine is an important mediator of the inflammatory response, and is
involved in a variety of cellular activities, including cell proliferation, differentiation, and
apoptosis [46]. Also, IL-1β activates nitric oxide synthase (NOS), which is implicated in
neuronal damage, ultimately leading to cell death in hippocampal neurons [47]. Furthermore,
IL-1β has been shown to play a part in the promotion of neuronal synthesis of β amyloid
precursor protein (APP) and may enhance the transition from diffuse to fibrillar neuritic
plaques [48]. Our data suggest that infection may play an early role in the etiology of AD,
even before amyloid is produced. This contrasts with others who have focused previously on
amyloid as being the principal stimulus for the activation of this cytokine [28].
The key debate, therefore, lies not in what this cytokine can activate and/or damage in the
brain, but rather what initiates its production. Levels of IL-1β have been shown to be higher
in the cerebrospinal fluid (CSF) of AD patients than in patients with vascular dementia or
control patients [49,50]. Our data show that IL-1β is significantly up-regulated at all times
through 120 hours post-infection of monocytes and thus is consistent with the cytokine
profile in AD, suggesting that infection can be an initiating stimulus for this cytokine.
Evidence suggests that IL-1β and IL-6 up-regulate the cdk5/p35 complex [51], a protein
kinase involved in tau hyperphosphorylation, a major pathological process observed in AD.
IL-6 also may be involved in neuronal degradation. IL-6 is an inflammatory cytokine that is
secreted by leukocytes and other various cell types during infection [52]. As a proinflammatory cytokine, IL-6 is secreted by T-cells, endothelial cells, and macrophages, which
stimulate an immune response to tissue damage leading to inflammation in the surrounding
area. IL-6 is an important mediator of fever and of the acute phase response. IL-6 can be
secreted by macrophages in response to specific microbial molecules, referred to as pathogen
associated molecular patterns (PAMPs), and can induce intracellular signaling cascades that
can further give rise to inflammatory cytokine production [53]. Infection with Cpn, as we
have determined in this study, influences significant secretion of this cytokine from infected
monocytes.
Not surprisingly, in our study, several gene transcripts were found to have significant fold
increases in the group consisting of the host defense against bacteria. These included:
DEFB4, DMBT1, PTAFR, and NFKBIA. DEFB4 is the transcript that codes for a defensin
protein with antimicrobial activity that has been shown to act as a cytokine linking innate and
adaptive immune responses [54]. Along these lines, Aβ amyloid 1-42 has been demonstrated
to have antibacterial properties and has been speculated to act as an anionic defensin [55].
However, whether Aβ 1-42 production and processing in LOAD results, in part, as an
antibacterial response is still debatable. Therefore, defensin transcript increases are intriguing
and warrant further study.

Up-regulation of DMBT1 takes place in response to activation of the intracellular pattern
recognition molecule NOD2 and consecutive NFkB-activation; this hinders bacterial invasion
and lipopolysaccharide (LPS)-induced TLR4 activation [56]. PTAFR is the gene for the
platelet activating factor receptor, which plays a role in the inflammatory response [57].
NFKBIA could lead to inhibition of the NFκB protein complex by trapping this transcription
factor in the cytoplasm, effectively leading to its inactivation. However, as NFκB activation
is upstream of gene transcription for IL-1β mentioned above, its complete inactivation by
NFKBIA up-regulation appears unlikely in our infected cells.
Another interesting entity found to be activated in infected cells is the inflammasome
complex. This is a cytoplasmic multi-protein complex that activates caspase-1, leading to the
processing and secretion of pro-inflammatory cytokines. These complexes are associated
with TLRs to mediate the response to extracellular and intracellular pathogens [58]. NLRC4
(NLR family, CARD domain containing 4) is involved in the regulation of caspase-1, which
upon activation results in processing and secretion of IL-1β. In this study, the NLRC4 gene
transcript showed significant fold increases. Previously, others have shown that NLRC4 is
required for the activation of caspase-1 and IL-1β secretion in response to bacterial flagellin
[59]. Interestingly, inflammasome activation also may arise as an outcome of amyloid
deposition and aggregation [60]. By orchestrating the activation of precursors of proinflammatory caspases, which in turn activate IL-1β, IL-18 and IL-33 secretion, the
inflammasome promotes a potent inflammatory response that influences the release of toxins
from glial and endothelial cells [61]. Although the NLRC4 inflammasome has been shown to
be activated by flagellated Gram-negative bacteria, recent studies have shown evidence for a
flagellin-independent pathway that activates the NLRC4 inflammasome after infection with
certain aflagellated bacteria [62]. As Cpn is an intracellular bacterium and aflagellated, our
data would support that of a flagellin-independent pathway. Another important response to
infection is one in which acute phase reactants are produced and secreted into blood. Of
these, serpins are included and constitute the largest superfamily of protease inhibitors in
humans [63,64]. In the microarray used in this study, SerpinA1 (Serpin peptidase inhibitor
clade A member 1) transcript was shown to increase significantly following infection. This
serpin is also known as α1-antitrypsin (AAT), a highly effective inhibitor of neutrophil
elastase and one that plays an important role in coagulation, inflammation, and turnover of
extracellular matrix. SerpinA1 also inhibits the activity of plasmin, thrombin, trypsin,
chymotrypsin, and plasminogen activator.
MCP1/CCL2 gene transcript in the family of cytokines and chemokines was significantly
increased following Cpn infection. This transcript was the most dramatically altered
following infection and has been recognized as a very important contributor to the
inflammatory response observed in AD [65]. The MCP1/CCL2 protein has been shown to be
increased in both CSF and plasma from individuals with mild cognitive impairment (MCI)
and AD [66]. While the exact effects of MCP1/CCL2 in the MCI/AD brain are not fully
understood, some experiments have shown that CCL2 may alter the properties of the BBB to
allow for increased monocyte migration into brain tissues [67]. Furthermore, this chemokine
may affect the production and clearance of Aβ amyloid from the brain [68]. Hence, although
we did not measure the protein directly, the dramatic increase in this transcript would suggest
that infection induction leading to such a large change is worthy of further evaluation.

Conclusion
Utilizing RT-PCR and ELISA techniques, our data demonstrate that Cpn infection of THP1
human monocytes promotes an innate immune response, as pro-inflammatory gene
transcripts and proteins showed significant fold increases. Furthermore, since research
suggests that a chronic inflammatory state is present within the AD brain [10] and prior
evidence has shown monocytes infected with Cpn in AD brains [1,3], we suggest that the
pro- and chronic inflammatory states involved in AD pathogenesis may arise in part by Cpn
infection of monocytes. These data are consistent with that of previous work suggesting that
amyloid could be both a response to and an initiator of inflammation in the AD brain [22]. In
effect, infection in the AD brain could initiate the inflammatory cascade that results in CNS
damage reflected by amyloid production/processing and deposition. Inflammation generated
by amyloid accumulation would then 'secondarily' result in extended damage via an
inflammatory response generating ever increasing AD neuropathology. Further research to
define the early events occurring in AD pathogenesis may help to clarify how infection with
Cpn, and possibly other pathogens, may be an initiator of inflammation in sporadic LOAD.
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